Management of status asthmatics in pediatric age group
Reading File
Finding Sources
Finding Sources
Searching PubMed
"status asthmaticus"[MeSH Terms] AND "child"[MeSH Terms] AND management
Reading File
Reading File
Reading File
Searching PubMed
"status asthmaticus" AND children AND treatment
Reading File
Reading File
Reading File
I now have comprehensive data. Let me compile the full, structured answer.
Management of Status Asthmaticus in Pediatric Patients
Definition
Status asthmaticus is an acute severe asthma exacerbation that fails to respond to usual doses of inhaled bronchodilators and corticosteroids. Features include hypoxemia, tachypnea, tachycardia, accessory muscle use, and wheezing (which may be absent when airflow is critically reduced).
Assessment and Severity Scoring
The Pediatric Asthma Score (PAS) is used to objectively grade severity and guide escalation:
| Component | Score 1 | Score 2 | Score 3 |
|---|---|---|---|
| RR (1-4 yr) | ≤34 | 35-39 | ≥40 |
| RR (4-6 yr) | ≤30 | 31-35 | ≥36 |
| RR (6-10 yr) | ≤26 | 27-30 | ≥31 |
| RR (>12 yr) | ≤23 | 24-27 | ≥28 |
| SpO2 | >95% RA | 90-95% RA | <90% or any O2 |
| Retractions | None/intercostal | Intercostal + substernal | + supraclavicular |
| Work of breathing | Full sentences | Partial sentences | Single words/grunting |
| Auscultation | Normal/end-expiratory wheeze | Expiratory wheeze | Inspiratory + expiratory wheeze or diminished |
A normalizing pCO2 (or rising pCO2) on blood gas in a tachypneic child signals impending respiratory failure.
Step-by-Step Management
Step 1 - Oxygen
- Maintain SpO2 ≥92-95%
- Deliver via nasal cannula, face mask, or non-rebreather
Step 2 - Short-Acting β2 Agonists (First-Line)
Albuterol is the cornerstone of treatment:
| Severity | Dose |
|---|---|
| Mild-Moderate | 0.15 mg/kg/dose (min 2.5 mg, max 5 mg) nebulized Q20 min x 3, then Q2-4 hr; or MDI 4-8 puffs (90 mcg/puff) Q20 min |
| Severe | Continuous nebulization: 0.5 mg/kg/hr (max 30 mg/hr) |
- MDI with spacer is preferred (equal or greater efficacy, fewer side effects, shorter LOS compared to nebulizer)
Step 3 - Anticholinergics (Add in Moderate-Severe)
Ipratropium bromide:
- Nebulizer: 0.25-0.5 mg; MDI: 4-8 puffs (17 mcg/puff)
- Give Q20 min x 3 doses alongside albuterol
- Note: No additional benefit shown in inpatient setting - primarily for the first few hours in the ED
Step 4 - Systemic Corticosteroids (Early and Essential)
| Drug | Dose | Notes |
|---|---|---|
| Dexamethasone | 0.6 mg/kg/day PO/IV/IM x 1-2 days (max 16 mg/day) | Preferred - equal efficacy to prednisone with better palatability/compliance |
| Prednisolone/Prednisone | 2 mg/kg/day PO x 5-7 days (max 60 mg/day); Severe: 2 mg/kg IV load (max 80 mg) then 2 mg/kg/day divided | Taper if course ≥7 days |
| Methylprednisolone | Q6-12 hr (max: <12 yr → 60 mg/day; ≥12 yr → 80 mg/day) | IV form for severe |
- No proven advantage to IV over oral route for corticosteroids if GI transit is normal
- Hydrocortisone for status: Load 4-8 mg/kg IV (max 250 mg), then 8 mg/kg/24 hr ÷ Q6 hr
Step 5 - Magnesium Sulfate (Adjunct for Severe)
- IV dose: 25-75 mg/kg/dose IV (max 2 g) infused over 20 minutes
- Adult/Tintinalli dosing: 1-2 g IV over 20-30 minutes
- Reduces hospitalizations in severe exacerbations
- Mechanism: smooth muscle relaxant (calcium antagonism)
- Monitor BP and deep tendon reflexes; hypotension is rare but possible - consider simultaneous fluid bolus
Step 6 - Injected β2 Agonists (Severe/Life-Threatening)
Used when there is minimal air entry and inhaled delivery is ineffective:
| Drug | Dose | Route |
|---|---|---|
| Epinephrine | 0.01 mg/kg of 1 mg/mL (max 0.5 mg) Q15-20 min x 3 doses | IM |
| Terbutaline | SQ: 0.01 mg/kg (max 0.25 mg/dose) Q20 min x 3 doses; IV load: 4-10 mcg/kg; IV infusion: 0.2-5 mcg/kg/min (up to 10 mcg/kg/min) | SQ or IV |
- IV terbutaline may decrease need for mechanical ventilation
Step 7 - Additional Adjunct Therapies
| Agent | Dose | Notes |
|---|---|---|
| Ketamine | 1-2 mg/kg IV load, then 1 mg/kg/hr infusion (titrated) | Bronchodilatory; preferred induction agent for intubation; useful for severe exacerbations refractory to standard therapy |
| Heliox | 70:30 or 80:20 (helium:oxygen) mixture | Low-density gas promotes laminar flow; improves β2 agonist delivery to distal airways; useful in severe/very severe exacerbations |
| Aminophylline | 6 mg/kg IV load over 20 min, then 0.5-1.2 mg/kg/hr infusion (age-dependent) | Associated with prolonged LOS and time to symptom improvement; use limited to refractory cases |
| Inhaled volatile anesthetics (isoflurane, sevoflurane) | Variable | Rescue therapy for intubated patients with life-threatening exacerbation; isoflurane: risk of hypotension; sevoflurane: risk of renal injury, hepatotoxicity |
Ventilation Interventions
Non-invasive Positive Pressure Ventilation (NIPPV/BiPAP)
- Indicated for impending respiratory failure to avoid intubation
- Requires a cooperative patient with spontaneous respirations
- Reduces work of breathing, improves oxygenation
- Also enhances delivery of aerosolized medications
Endotracheal Intubation - Indications
- Respiratory arrest or near-arrest
- Severe hypoxia unresponsive to therapy
- Rapidly declining mental status
- Severe air trapping with impending barotrauma
RSI Protocol for Status Asthmaticus
| Time | Step |
|---|---|
| -10 min | Preparation |
| -5 min | Preoxygenation: continuous albuterol nebulizer + 100% O2 by NRB mask or BiPAP |
| -3 min | Pre-intubation optimization: albuterol 2.5 mg nebulized, IV epinephrine or SQ terbutaline |
| 0 | Induction: Ketamine 1.5 mg/kg + Succinylcholine 1.5 mg/kg |
| +45 s | Laryngoscopy and intubation + ETCO2 confirmation |
Key ventilator settings post-intubation:
- Low tidal volume, low respiratory rate - to allow adequate exhalation
- High inspiratory flow rate
- "Permissive hypercapnia" - tolerate rising CO2 to prevent auto-PEEP (breath stacking/air trapping)
- Long-term neuromuscular blockade may be needed to allow ventilation
- Continuous epinephrine infusion may be required
Disposition
| Response | PEFR/FEV1 | Action |
|---|---|---|
| Good response | >70% predicted | Discharge with action plan |
| Incomplete response | 40-69% predicted | Observation unit vs. hospitalization |
| Poor response | <40% predicted | Hospitalize (consider PICU) |
- Arrange follow-up with PCP or asthma specialist within 1-4 weeks
- Provide written asthma action plan
- Review inhaler technique, spacer use, and triggers
Agents With No or Uncertain Benefit
- Antibiotics: Not indicated unless clear bacterial infection
- Lidocaine: No high-level evidence to support use during RSI to blunt airway reflexes
- Methylxanthines (aminophylline): Associated with increased LOS - use only for refractory cases
Recent Evidence (2025)
Two recent systematic reviews are notable:
- Abu-Sultaneh et al. (2025) - Intravenous Bronchodilators in Pediatric Critical Asthma: A Network Meta-Analysis [PMID: 40637351] - addresses comparative efficacy of IV bronchodilators (terbutaline, magnesium, etc.)
- Maue et al. (2025) - Protocols and Pathways in Pediatric Critical Asthma [PMID: 40643011] - systematic review supporting protocol-driven management in pediatric critical asthma
Sources: The Harriet Lane Handbook 23rd ed. (Tables 1.6, 1.7) | Tintinalli's Emergency Medicine (Ch. 69) | Rosen's Emergency Medicine
This is a shared conversation. Sign in to Orris to start your own chat.